Searched for
CEQUA THERAPY
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsGiven multiple issues that have suddenly come up, there is a high probability that the market will remain volatile. But history tells us th...- Strong balance sheet, brand & management are enough to create wealth: 8 stocks with upside potential from just 2% to 32%A good stock is only good in a time frame – the time frame in which it gets you returns. A good company is one which fares well even in a d...
- Sun Pharma stares at 8-10% profit risk amid 100% Trump tariffs, says HSBC. Can the giant navigate this?Sun Pharma faces potential impact from the US 100% tariff on patented drugs, which could reduce FY26–27 earnings by 8–10%. Generic drugs re...
- Jefferies unveils 8 new buy calls, expands list to 25 stocks. Check full listJefferies has refreshed its equity strategy, adding 8 new stocks to its list of 25 top buy ideas from a universe of 223. The brokerage’s pi...
- Sun Pharma's focus on specialty drugs pays offThe company's revenues grew 11% driven by strong growth posted by the India business and the global specialty sales in the US. A third of t...
- 4 reasons Sun Pharma is this week's stock pickSun Pharma’s 2022 annual report estimates that the global pharmaceutical market will grow by $400 billion between 2021 and 2026.
- Sun Pharma launches novel therapy for dry eye disease in IndiaDED is caused when the quantity or quality of tears fails to keep the surface of the eye properly lubricated, and associated with symptoms ...
- Why Nithya Balasubramanian is gung-ho on Sun Pharma & Cipla“One gets different types of exposure with Sun Pharma and Cipla. For Sun, the capital allocation into US specialty is now bearing fruit. At...
- Does Sun Pharma's specialty portfolio hold key to its performance?According to the FY 2022 annual report of Sun Pharma, it is ranked number 1 in terms of prescriptions with an 8.34% market share in India. ...
- As Covid sales spike ebbs, what lies ahead for pharma companies?Indian pharmaceutical market flattened after the pandemic led to a massive upsurge in demand for drugs. The industry saw a rise in sales du...
- Sun Pharma Q3 Results Preview: Net profit may fall 7%; sales seen rising 8-9%Net sales for the pharma major is seen rising 9.04 per cent YoY to Rs 9,635 crore from Rs 8,836 crore in the same quarter last year. Ebitda...
- Sun Pharma, other drug cos say innovative products to contribute substantially in futureSun Pharma, India's largest drug maker, said it expects its innovative products to garner $1.5 billion in sales in the next 3-4 years.
Load More
